  Discovering novel drug candidate molecules is one of the most fundamental and
critical steps in drug development. Generative deep learning models, which
create synthetic data given a probability distribution, have been developed
with the purpose of picking completely new samples from a partially known
space. Generative models offer high potential for designing de novo molecules;
however, in order for them to be useful in real-life drug development
pipelines, these models should be able to design target-specific molecules,
which is the next step in this field. In this study, we propose DrugGEN, for
the de novo design of drug candidate molecules that interact with selected
target proteins. The proposed system represents compounds and protein
structures as graphs and processes them via serially connected two generative
adversarial networks comprising graph transformers. DrugGEN is trained using a
large dataset of compounds from ChEMBL and target-specific bioactive molecules,
to design effective and specific inhibitory molecules against the AKT1 protein,
which has critical importance for developing treatments against various types
of cancer. On fundamental benchmarks, DrugGEN models have either competitive or
better performance against other methods. To assess the target-specific
generation performance, we conducted further in silico analysis with molecular
docking and deep learning-based bioactivity prediction. Results indicate that
de novo molecules have high potential for interacting with the AKT1 protein
structure in the level of its native ligand. DrugGEN can be used to design
completely novel and effective target-specific drug candidate molecules for any
druggable protein, given target features and a dataset of experimental
bioactivities. Code base, datasets, results and trained models of DrugGEN are
available at https://github.com/HUBioDataLab/DrugGEN
